Hypha Discovery Ltd

Hypha collaborates with pharma/biotech and agrochemical groups in the following areas

1. Production of metabolites of clinical and preclinical stage compounds that are difficult to synthesise using metabolising microbes:
+ mg amounts for MetID, quantification standards
+ gram quantities for tox/pharmacological studies
+ includes glucuronides and chemically intractable hydroxyl derivatives 

Our microbial biotransformation service is also used to improve PK/solubility in hit-to-lead compounds 

2. Niche natural products hit-finding
Licensing access to Hypha's MycoDiverse natural products library. 
+ Used by biotech and pharma to find hit compounds against "difficult-to-hit" targets
+ Molecular weight range mostly between 200 and 400 DA
+ 50% novelty
+ Exclusive rights to develop and commercialise

3. Fermentation and purification of small molecules for semi-synthetic lead optimisation

Dr Liam Evans
CEO 

Illingworth Research

Founded as Clinical Development & Support Services Ltd (CDSS)  in 1998, Illingworth Research is a Clinical Research Organisation (CRO) providing a wide range of clinical development services to the pharmaceutical, healthcare, biotechnology and medical device industries. We are experts in the management of Phase I to IV clinical trials across many different therapeutic areas.
From our base in Cheshire UK, where we are co-located with our sister company ResearchNurses.co, we offer the ultimate clinical research outsourcing partnership for sponsors across the globe. 
We have worked with all types of clients, from start-up biotechnology companies to large international pharmaceutical companies, providing strong sponsor/CRO partnerships to deliver a competitive advantage.

Company type
Mr Kieran Casey
Director Business Development 

Image Analysis Ltd

'Effective use of imaging to understand if the drug works'

 We offer advanced medical image analysis techniques and propriety technology platform to improve study economics, to facilitate greater quality control and objectivity of the outcomes.

 

Image Analysis team support Sponsors in setting up technology supported clinical studies , where image scoring is done using computer-aided algorithms and image management is standardized, automated and centralized with the company’s proprietary platform Dynamika.

Company type
Dr Aidan Ancill
Head of operations and business solutions 

MGB Biopharma

MGB Biopharma is a private company based in Glasgow, Scotland and is backed by a syndicate of Scotland’s leading angel investor groups together with Scottish Enterprise.

Antimicrobial drug resistance is recognised as a global public health concern with an urgent need for new antibacterial drug classes that are more effective than existing treatments. MGB is developing the first truly novel class of anti-infectives in over a decade that has the potential to treat infections of a number of the most important susceptible and resistant pathogens. Our lead compound has shown strong bactericidal activity with quick onset of action against many strains of Gram-positive bacteria. It has completed pre-clinical development and progress into our phase 1 clinical study for the treatment of Clostridium difficile have been endorsed by the MHRA. Optimisation of a new formulation for intravenous administration and treatment of systemic Gram-positive infection is ongoing.

MGB has acquired exclusive rights to the proprietary minor groove binder platform, developed at the University of Strathclyde, Glasgow. This platform provides an opportunity to develop additional compounds with the potential to treat Gram-negative, viral, fungal and parasitic infections.

MGB continues to work closely with Strathclyde University to develop the pipeline and is currently seeking partners to help maximise the value-creating opportunities from its broad platform.

Company type
Dr Miroslav Ravic
Mr Raymond Spencer

MiNA Therapeutics

MiNA Therapeutics is a virtual biotechnology company pioneering the activation of gene expression with short activating RNA (saRNA).

Harnessing a proprietary algorithm, MiNA is developing a revolutionary class of therapeutics that activate key genes in major disease pathways. MiNA's ability to selectively activate master regulatory genes represents a new frontier in precision medicine.

MTL-501 is a saRNA liver cancer therapeutic that activates the CEBPA gene. Intravenous injection of MTL-501 in a liver cancer rat model reduced tumour burden by 80% whilst increasing significantly serum albumin. In vitro work has indicated the dramatic potential of CEBPA saRNA as a universal anti-cancer therapeutic in non-small cell lung, prostate, pancreas, leukaemia, lymphoma and glioblastoma. MTL-301 is a Type 1 diabetes therapeutic. In vitro work demonstrated glucose responsive insulin secretion by both CD34+ adult stem cells and HepG2 cells.
Website:
www.minatx.com
Company type
Mr Robert Habib
CEO 

Nova Language Services

Are you on the lookout for a specialised Localization and multilingual translation partner who can handle 100 plus language combinations? 
Can supply certified translations under UNE 15038 and ISO9001 has 14 years’ experience working in pharma, medical device and clinical trial sectors. 
Can understand the importance of a quality process and critical attention to detail under tight timelines with competitive pricing!
Is Big enough to meet your needs but small enough to care!
Look no further lets’ meet at Bio Europe 2013 and discuss how NOVA could help you with your translation and interpretation requirements.

Company type
Mr Arun Mathew
International Sales Manager 

Novozymes Biopharma UK

Novozymes Biopharma develops and manufactures sustainable, safe, biological based ingredients and technologies to provide pharmaceutical and medical device manufacturers the knowledge-based solutions needed to address the challenges in developing innovative, safer, and more consistent final products. The company's large-scale manufacturing facilities worldwide are run to cGMP Q7 quality standards to ensure that customers receive the highest level of product quality and consistency, as well as the security of long-term supply. Novozymes’ customer-integrated approach combines the company’s scientific know-how and the specific needs of customers to deliver improved products and performance. By combining Novozymes’ unique knowledge around our biological solutions such as recombinant albuminhalf-life extension and hyaluronic acid with the specific application knowledge of our customers, we work with companies to deliver improved performance and safety for next generation of medical device and pharmaceutical products.
Dr Dave Mead
Business Development Director 
Ms Tara Sharpe
Business Development Manager 

Ockham Oncology

Ockham provides high-quality, global clinical research and strategic development services to pharmaceutical and biotechnology companies, assisting them in the achievement of their strategic planning, technology transfer, licensing, regulatory planning and submissions, pre-clinical development, and manufacturing goals. 

Ockham also provides fully integrated clinical trials support in the areas of Clinical Operations, Data Management and Biostatistics, as well as Regulatory dossier compilations. In addition, it offers functional and specialty resourcing services to pharmaceutical, biotech and medical device companies that require Clinical Operations, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), or Good Manufacturing Practice (GMP) auditing, Data Management, Statistical Programming, Biostatistics, and Medical Writing solutions.

Website:
www.ockham.com
Company type
Ms Andrea Cotton-Berry
Global Director, Client Services 
Mr Mike Baker
Vice President 

Oxford BioMedica plc

Oxford BioMedica (LSE:OXB) is a leading gene therapy and immunotherapy company with a platform of exclusive and pioneering technologies to design, develop and manufacture unique gene-based medicines. The Company’s technology platforms include a highly efficient LentiVector® gene delivery system; a single administration to provide long-lasting therapy with specific advantages for targeting CNS and ocular diseases, and a unique tumour antigen (5T4) which is an ideal target for anti-cancer therapy.

The Company’s pipeline addresses diseases for which there is currently no treatment or that are inadequately treated today, including ocular diseases, neurodegenerative disorders and cancer, and its product candidates have the potential to transform treatment landscapes.  Oxford BioMedica’s capabilities cover the entire product lifecycle, from research to development to GMP manufacturing, with collaborative partners such as Sanofi, Pfizer, Novartis and some of the most prestigious clinical centres worldwide.  The Company recently secured significant funding via UK Government competitive awards such as the TSB regenerative medicine/cell therapy grant and AMSCI to build a centre of excellence for specialist manufacture of gene-based therapies.

Through in-house development programmes and industry collaborations, Oxford BioMedica’s goal is to improve the lives of patients with debilitating and life-threatening diseases.  Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.

Dr Alex Lewis
Director of Corporate Activities & Strategy 
Mr Peter Nolan
SVP - Commercial Development 

Purolite


A leader in ion exchange and resin technology—and one of the world’s largest
developers and manufacturers of high-quality APIs, blood purification polymers, enzyme carriers, chromatographic resins and ion exchange products—Purolite is introducing the new product line based on agarose in our cGMP, FDA regulated facility.
With three strategically located production plants, five global R&D centers—including a research center of excellence in the UK—and a sales force made up of industry experts, Purolite is your solutions company for quality products, stability of manufacturing and knowledgeable service.

Developed and manufactured by Purolite, innovative agarose-based biochromatography resins will expand the LifeTech family of products to cover SEC, HIC, IEX and affinity bio-purification media for the fast-growing biosimilars market.
LifeTech bio-based resins will support customer needs—from drug development with pre-packed columns, to bulk media for industrial production of biosimilars.

Website:
www.purolite.com
Company type
Dr Alessandra Basso
LifeTech Manager